Compass Pathways PLC (NASDAQ: CMPS) is a mental health care company that is focused on improving patient access to evidence-based innovation in mental health. The company’s stock, which trades as CMPS on the NASDAQ has been performing well, with many attributing this positive performance to the appointment of a new CEO.
The company recently announced that it would be launching a new phase 2 trial on the use of its COMP360 formulation in treating anorexia. The company will conduct the trial at various prestigious research institutions in the United States and the United Kingdom, including Columbia University’s Irving Medical Center, King’s College London, Sheppard Pratt and University of California San Diego School of Medicine.
Anorexia nervosa is a severe mental health condition that is characterized by serious restriction of calorie intake and a preoccupation with shape and weight. The condition carries the highest rate of mortality in all psychiatric illnesses at 5.8%, as it leads to suicide and medical complications. Figures show that about 30% of deaths in anorexia are from suicide.
Currently, anorexia has no approved pharmacological treatments, with data showing that roughly 0.3% and 2.2% of men and women respectively suffer from the condition globally.
In its announcement, the company stated that the double-blind, multicenter, randomized controlled phase 2 clinical trial would investigate the effectiveness of its psilocybin formulation in treating individuals with anorexia nervosa when administered in combination with psychological support.
This new trial adds to the company’s development pipeline, which comprises of its advanced psilocybin trial evaluating the formulation’s efficacy in treating depression. The company plans to recruit 60 participants who all suffer from anorexia nervosa. The researchers will measure any symptom changes that are observed using measures such as the Eating Disorder Examination interview.
The trial’s objective is to compare the effects of 1 mg and 25 mg of its COMP360 formulation when administered with psychological support. Change from baseline in the Eating Disorder Examination global score during the fourth week after the psilocybin therapy has been administered is the study’s primary endpoint.
Company chief medical officer, Dr. Guy Goodwin, stated that the company was determined to develop a pharmacological treatment option for anorexia nervosa. He explained that carrying out this trial would help researchers understand if their psilocybin formulation could help individuals living with anorexia nervosa, when combined with psychological support.
This trial will be the first to use a digital app known as myPathfinder, which was developed by the company. The application supports patients during their psilocybin therapy process.
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
The acquisition of Cohen and Associates, a respected interventional psychiatry practice, by NRx subsidiary HOPE…
The new FDA voucher program aims to speed approval of drugs aligned with national health…
The company targets all current ketamine indications, including anesthesia and pain management. The U.S. is…
The Kadima Neuropsychiatry Institute acquisition is part of NRx subsidiary HOPE Therapeutics’ model for a…
Subsidiary HOPE Therapeutics signed a $7.8 million debt financing term sheet with Universal Capital. Combined…
Kadima Neuropsychiatry Institute is expected to become the clinical model for HOPE Therapeutics’ nationwide network…